SUBSCRIBE
SUBSCRIBE
News   FDA

Swiss Approve Novartis International AG Drug For Blindness

August 29, 2006 | 
1 min read
ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50.
FDA Approvals Europe
MORE ON THIS TOPIC
Laptop with envelope and document with exclamation mark on screen. Receive notification, alert message, warning, get e-mail, email, spam concepts. Flat design vector illustration
FDA
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy
July 27, 2026
 · 
3 min read
 · 
Heather McKenzie
3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
July 27, 2026
 · 
3 min read
 · 
Gabrielle Masson
A silhouette of a head with a pink brain inside, surrounded by various graphic elements, a light bulb, puzzle pieces, speech bubbles, a key and abstract doodles. The concept of thinking, creativity.
Approvals
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
July 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Business competitive advantage of paper plane in new competitive, competitor individual pointing in different ways for new competitive advantage on 3D render. Advantage for new idea competition.
Insights
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
July 27, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker